• Completed dual listing Frankfurt Stock Exchange ticker PR8.F
• Expanded capacity (GMP clean rooms +100%, storage +200%)
• Entry into UK, Germany, LATAM and new contract wins
• Record half driven by sustained and rising demand
• Commercial release and supply of the first Australian-made GMP-certified MDMA capsules

Bioxyne Ltd reported a strong H1 FY2026 performance, with revenue of A$31.3m (+149% vs. PCP) and NPAT of A$7.3m (+121% vs. PCP). The results were driven by increasing demand for the company's GMP-manufactured medicinal cannabis, MDMA, and psilocybin products, as well as its demonstrated ability to scale manufacturing and distribution capacity efficiently. Key highlights include the completion of a dual listing on the Frankfurt Stock Exchange (ticker PR8.F), expansion of GMP clean room and storage capacity by 100% and 200% respectively, and entry into new markets such as the UK, Germany, and Latin America with new contract wins. The company also achieved a major milestone with the commercial release and supply of the first Australian-made GMP-certified MDMA capsules in H1 FY26. Bioxyne has revised its FY26 Adjusted EBITDA guidance upwards to A$16.5m-A$19m (previously A$11.5m-A$13.5m), reflecting the strong performance and outlook.

FY26 Revenue guidance: A$65m - A$75m FY26 Adjusted EBITDA guidance: A$16.5m - A$19m

Bioxyne is focused on increasing its market share in Australia, securing new manufacturing contracts and driving growth of white label product lines with higher unit economics. The company is also scaling its Dr Watson® branded prescription medicines via clinics, pharmacies, and clients, and expanding its presence in the UK and German markets. Bioxyne plans to own and operate company-owned GMP manufacturing and distribution facilities in the UK and Europe to further drive growth.